Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.55 |
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | TDO2 | P48775 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230487 | 0.93 | IDO1 (0.52) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL230516 | 0.93 | CES2 (0.50) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL230519 | 0.91 | CES2 (0.49) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL18623174 | 0.89 | CA1 (0.49) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL229195 | 0.88 | ACHE (0.59) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL20862602 | 0.88 | CES2 (0.46) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL230488 | 0.88 | OPRM1 (0.47) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL23882733 | 0.86 | CYP11B1 (0.46) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL6349980 | 0.86 | CES2 (0.45) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL18280131 | 0.86 | CYP11B1 (0.46) | CES2CES1HDAC4HDAC7HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| US-11420950-B2 | Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2022-08-23 | — | — | US | disclosed |
| CN-108026057-B | Heterocycloalkyl-derived compounds as selective histone deacetylase inhibitors and pharmaceutical compositions containing the same | 株式会社钟根堂 | 2021-08-06 | — | — | CN | disclosed |
| EP-3814348-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-112654621-A | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2021-04-13 | — | — | CN | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-20040039014-A1 | Methods and compounds for treating depression and other disorders | NPS PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2003-03-13 | — | — | US | disclosed |
| US-6417213-B2 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20020006944-A1 | Tricyclic compounds, their production and use | OHKAWA SHIGENORI (JP) | 2002-01-17 | — | — | US | disclosed |
| EP-1162196-A1 | FUSED-RING COMPOUNDS AND USE THEREOF AS DRUGS | JAPAN TOBACCO INC. (JP) | 2001-12-12 | — | — | EP | disclosed |
| US-6248766-B1 | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| EP-1096926-A2 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMACEUTICALS, INC. (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000002551-A2 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMACEUTICALS, INC. (US) | 2000-01-20 | — | — | WO | disclosed |
| EP-0929534-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013356-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | CES2 4302/4885CES1 2736/4885HDAC4 2391/4885 |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, HLA-C | CES2 667/4885CES1 318/4885HDAC4 718/4885 |
| US-20020006944-A1 | Tricyclic compounds, their production and use | CNR1, PTGER1, PTGDR | CES2 1878/4885CES1 961/4885HDAC4 1926/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | CES2 4302/4885CES1 2736/4885HDAC4 2391/4885 |
| US-11420950-B2 | Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same | HDAC1, HDAC3, HDAC5 | CES2 3792/4885CES1 1396/4885HDAC4 6/4885 |
| US-20040039014-A1 | Methods and compounds for treating depression and other disorders | GRIN1, GRIN2C, GRIN3B | CES2 937/4885CES1 2902/4885HDAC4 243/4885 |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | CES2 4302/4885CES1 2736/4885HDAC4 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.